New hope for hodgkin lymphoma: immunotherapy drug outperforms standard treatment?
NCT ID NCT02684292
First seen Jan 07, 2026 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tested two drugs—pembrolizumab and brentuximab vedotin—in 304 people with Hodgkin lymphoma that had returned or not responded to prior treatment. The goal was to see which drug better delayed cancer growth and improved survival. Participants received treatment for up to 2 years. Results help doctors choose the best option for managing this blood cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.